Inventiva S.A. (NASDAQ:IVA) Short Interest Update

Inventiva S.A. (NASDAQ:IVA) was the recipient of a large decline in short interest in the month of November. As of November 15th, there was short interest totalling 390,300 shares, a decline of 9.2% from the October 31st total of 429,900 shares. Based on an average trading volume of 207,600 shares, the short-interest ratio is currently 1.9 days.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on IVA shares. Stifel Nicolaus reduced their price target on Inventiva from $20.00 to $17.00 and set a “buy” rating on the stock in a research note on Friday, November 22nd. UBS Group initiated coverage on Inventiva in a research report on Tuesday, November 12th. They set a “neutral” rating and a $3.00 target price on the stock. Finally, HC Wainwright lowered their price target on Inventiva from $14.00 to $13.00 and set a “buy” rating for the company in a report on Tuesday, October 15th. One research analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $13.25.

Institutional Trading of Inventiva

An institutional investor recently bought a new position in Inventiva stock. Virtu Financial LLC purchased a new position in shares of Inventiva S.A. (NASDAQ:IVA) in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 10,490 shares of the company’s stock, valued at approximately $38,000. 19.06% of the stock is currently owned by institutional investors and hedge funds.

Inventiva Trading Up 0.4 %

Shares of Inventiva stock opened at $2.62 on Wednesday. The business’s fifty day moving average price is $2.44 and its 200 day moving average price is $2.60. Inventiva has a twelve month low of $1.53 and a twelve month high of $4.75.

About Inventiva

Inventiva SA, a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI.